Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP to Report Third Quarter 2016 Financial Results on November 17, 2016
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Report Third Quarter 2014 Results on November 20, 2014
Conference Call and Webcast Scheduled for 8:30 a.m. EDT
View HTML
Toggle Summary EDAP to Report Second Quarter 2016 Financial Results on August 25, 2016
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Report Fourth Quarter and Full-Year 2014 Results on April 2, 2015
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Report Fourth Quarter and Full Year 2015 Results on April 4, 2016
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Report First Quarter 2016 Results on May 18, 2016
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Report First Quarter 2015 Results on May 13, 2015
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP to Raise $9.3 Million in Registered Direct Offering
LYON, France , May 28, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of 3 million of ordinary shares in the form of
View HTML
Toggle Summary EDAP to Raise $12 Million in Registered Direct Offering
LYON, France , May 21, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of $12 million of ordinary shares in the form of
View HTML
Toggle Summary EDAP to Present Prostate Cancer Data At American Urological Association Annual Meeting
High Intensity Focused Ultrasound Offers a Potentially Effective, Minimally Invasive Alternative to Existing Prostate Cancer Therapies
View HTML